Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie has licensed an experimental anti-TL1A antibody from FutureGen Biopharmaceutical, the latest bet on a drug target that has attracted intense pharma…
AbbVie is betting on TL1A as a next-generation inflammatory bowel disease target, licensing FutureGen Biopharmaceutical's preclinical anti-TL1A antibody…
AbbVie has struck a licensing deal worth up to $1.71 billion with FutureGen Biopharmaceutical Shanghai Co. Ltd. for FG-M701, a preclinical next-generation…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AbbVie and FutureGen announced exclusive global license agreement for FG-M701, a next-generation fully human anti-TL1A monoclonal antibody in preclinical development for IBD. FutureGen receives $150M upfront/near-term plus up to $1.56B in development, regulatory and commercial milestones and tiered royalties up to low-double digits. AbbVie assumes global dev/mfg/commercialization rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / FutureGen Biopharmaceutical (Shanghai) Co. Ltd. (this deal) | 2024 | $1.7B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · AbbVie Inc. deals · Gastroenterology deals